NurExone Biologic (FRA:J90) Total Operating Expense: €5.49 Mil (TTM As of Mar. 2026)


FRA:J90 NurExone Biologic Inc FRA:J90
34 GF Score
Price €0.31
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic Total Operating Expense?

NurExone Biologic FRA:J90 34 Total Operating Expense is €5.49 Mil as of Mar. 2026. GuruFocus rates FRA:J90 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

NurExone Biologic's Total Operating Expense for the three months ended in Mar. 2026 was €1.52 Mil. NurExone Biologic's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €5.49 Mil.

NurExone Biologic Total Operating Expense Related Terms

NurExone Biologic Total Operating Expense Historical Data

* Premium members only.

The historical data trend for NurExone Biologic's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Total Operating Expense Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
1.52 5.23 3.35 4.78 5.40

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.58 1.25 1.14 1.52
FRA:J90
34GF Score
NurExone Biologic Inc FRA:J90
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €5.49 Mil mean?
NurExone Biologic (FRA:J90) has a Total Operating Expense of €5.49 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on NurExone Biologic and its competitors.
Is NurExone Biologic's Total Operating Expense too high?
NurExone Biologic's current Total Operating Expense is €5.49 Mil. Overall, NurExone Biologic has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's Total Operating Expense compare to VRTX and REGN?
NurExone Biologic's Total Operating Expense of €5.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on NurExone Biologic and its competitors. NurExone Biologic's current Total Operating Expense is €5.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current Total Operating Expense of €5.49 Mil. The current Total Operating Expense is €5.49 Mil. NurExone Biologic's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Total Operating Expense is €5.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
34GF Score

Get the complete analysis for FRA:J90

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.31
Price